There is no FDA-approved thymosin alpha 1 COVID dosage. See the 1.6 mg regimens used in COVID-19 trials, how long they lasted, and what research shows.
There is no FDA-approved thymosin alpha 1 COVID dosage. In published COVID-19 research, the most frequently reported regimen is 1.6 mg injected subcutaneously once daily for 5 to 7 days, added to standard hospital care, with some protocols using 1.6 mg twice daily. Those numbers come from small trials and retrospective chart reviews, not from large randomized dose-finding studies, so no official dosing standard exists.
What Researchers Actually Used in COVID-19 Studies
Thymosin alpha 1 (Tα1, also called thymalfasin or sold as Zadaxin) is a synthetic 28-amino-acid peptide studied for decades as an immune modulator. Interest in thymosin alpha 1 covid research surged in early 2020, largely because Tα1 was already licensed in China and Italy for hepatitis and was easy for hospitals to add to existing protocols.
Nearly every COVID-19 protocol reused the fixed 1.6 mg dose from hepatitis research rather than testing new dose levels. A thymosin alpha 1 dosage chart in the medical literature usually just lists these same regimens side by side.
Most questions about thymosin alpha 1 dosage covid trace back to the same handful of hospital protocols, which is why the same 1.6 mg figure keeps appearing.
| Setting | Route | Reported regimen | Notes |
|---|---|---|---|
| Severe COVID-19, China, 2020 (retrospective) | Subcutaneous | 1.6 mg once daily for 5–7 days | Added to standard care; immune lab markers improved, mortality results mixed |
| Severe to critical COVID-19, China, 2020 | Subcutaneous | 1.6 mg twice daily for 5 days, then 1.6 mg once daily | Some protocols ran 10 days total; no dose-finding phase |
| Nebulized Tα1, investigational | Inhaled / nebulized | 1.6 mg nebulized once or twice daily for 5–7 days | Very small studies; lung deposition and absorption not standardized |
| Post-COVID or long COVID, case series | Subcutaneous | 1.6 mg once or twice weekly for 4–12 weeks | No consensus regimen; highly variable |
| Chronic hepatitis B (Zadaxin label, non-COVID) | Subcutaneous | 1.6 mg twice weekly for 6 months | Reference regimen that COVID research borrowed from |
Two patterns stand out. First, the dose was almost always fixed at 1.6 mg instead of being scaled to body weight. Second, treatment windows were short, usually under two weeks, because the goal was to influence the early immune response rather than treat a chronic infection.
Why No Single Dose Is Considered Standard
Route, timing, and clinical goal all change the numbers. COVID-19 trials were never designed to compare one dose against another, which is why a single accepted regimen has never emerged.
- Subcutaneous injection: the most studied route, with 1.6 mg per injection as the default in nearly every protocol.
- Nebulized or inhaled: used in a handful of small Chinese studies at 1.6 mg per session, sometimes twice daily.
- Nasal spray: there is no standardized thymosin alpha 1 nasal spray dosage because no nasal product has been formally evaluated in a controlled COVID-19 trial.
- Frequency: daily dosing during acute illness versus twice-weekly dosing for chronic conditions such as hepatitis.
A recurring frustration is that people want a simple dose-per-kilogram rule, but Tα1 does not work that way in the published data. The 1.6 mg figure is a commercial formulation standard, not a pharmacologically optimized dose.
Is Thymosin Alpha 1 Approved or Proven for COVID-19?
Thymosin alpha 1 is not FDA-approved for human use in the United States for any indication, including COVID-19. It is licensed in a few countries, most notably China and Italy (as Zadaxin), for chronic hepatitis B and C and sometimes as an immune adjuvant.
Evidence in COVID-19 remains weak by regulatory standards:
- Most studies were retrospective, single-arm, or very small, with a high risk of bias.
- Some reported faster recovery of lymphocyte counts or lower mortality in severe patients; others found no meaningful difference.
- No large, randomized, placebo-controlled trial has established a proven thymosin alpha 1 COVID-19 dosage or benefit.
Researchers have described Tα1 as a promising immune modulator worth further study — not as an established COVID-19 treatment.
What About Long COVID?
Data on thymosin alpha 1 long covid use remain limited to small case series and pilot studies. The rationale is that persistent immune dysregulation may contribute to lingering symptoms, so an immune modulator might help a subset of patients.
Reported regimens in that setting vary widely, from 1.6 mg once weekly to 1.6 mg twice weekly for four to twelve weeks. Because long COVID is defined by symptoms rather than a single lab marker, measuring whether Tα1 helps is difficult, and no professional society recommends it.
How Tα1 Compares With Other Thymic Peptides
When people ask about thymosin alpha 1 vs thymosin beta 4, the short answer is that they are different molecules with different jobs. Thymosin alpha 1 is studied for immune signaling, while thymosin beta 4 is studied mainly for tissue repair, cell migration, and wound healing.
That difference shows up in dosing. Tα1 is used at a fixed 1.6 mg in most human protocols, whereas thymosin beta 4 research often uses weight-based or higher milligram amounts depending on the route and target tissue. The two peptides are not interchangeable, and neither is approved for COVID-19.
Safety and Realistic Expectations
Across hepatitis and COVID-19 studies, Tα1 has generally been described as well tolerated. Reported side effects include injection site reactions, mild flu-like symptoms, and rare allergic reactions.
Several cautions matter:
- People with autoimmune conditions or those on immunosuppressive therapy should not use Tα1 without specialist guidance, since its effects on immune balance are not fully understood.
- Gray-market peptides may be mislabeled, underdosed, or contaminated; a 1.6 mg label does not guarantee 1.6 mg of pure peptide.
- Self-dosing based on a research protocol is not the same as participating in a monitored clinical trial.
Anyone considering thymosin alpha 1 for COVID-19, long COVID, or any other reason should talk with a licensed healthcare professional first. The honest summary is that the studied dose range is narrow, the evidence is preliminary, and no regulatory agency has approved this peptide for COVID-19.
Frequently Asked Questions
What dosage of thymosin alpha 1 was used in COVID-19 studies?
Most published COVID-19 protocols used 1.6 mg injected subcutaneously once daily for 5 to 7 days, and some severe-case protocols used 1.6 mg twice daily before tapering to once daily. A few small studies delivered 1.6 mg by nebulizer instead. These are research protocols, not approved treatment recommendations.
Is thymosin alpha 1 approved for COVID-19 in the United States?
No. Thymosin alpha 1 (thymalfasin) is not FDA-approved for human use in the United States for any indication, including COVID-19. It is licensed in some other countries, such as China and Italy, for chronic hepatitis B and C under the brand name Zadaxin.
Can thymosin alpha 1 nasal spray be used for COVID-19?
There is no standardized nasal spray dosage and no approved nasal thymosin alpha 1 product, so any nasal or inhaled use is experimental. Published inhaled studies were small, used 1.6 mg per session, and did not establish consistent absorption or benefit. Talk to a healthcare professional before considering any unapproved route.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.